Structure Therapeutics Inc. (GPCR): Cash & Equivalents

Annual figures by period end, from SEC filings.

$799.62M

As of 2025-12-31

$272.64M

As of 2026-06-30

+212.9%

3-year compound annual growth

2022-12-31 Cash & Equivalents (USD) 2025-12-31

Period ended	Cash & Equivalents	Change YoY	Source filing
2025-12-31	$799.62M	+371.7%	2026-02-26, Balance as of period end
2024-12-31	$169.51M	+30.6%	2026-02-26, Balance as of period end
2023-12-31	$129.79M	+397.5%	2025-02-27, Balance as of period end
2022-12-31	$26.09M	n/a	2024-03-08, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cash & Equivalents	Change YoY
Structure Therapeutics Inc. (GPCR)	2025-12-31	$799.62M	+371.7%
Acadia Pharmaceuticals Inc (ACAD)	2025-12-31	$177.69M	-44.4%
Ligand Pharmaceuticals Inc (LGND)	2025-12-31	$174.93M	+141.9%
Amphastar Pharmaceuticals, Inc. (AMPH)	2025-12-31	$170.18M	+12.2%
Innoviva, Inc. (INVA)	2025-12-31	$550.94M	+80.7%
Ultragenyx Pharmaceutical Inc. (RARE)	2025-12-31	$421.00M	+142.0%
Collegium Pharmaceutical, Inc (COLL)	2025-12-31	$231.25M	+227.7%
Phibro Animal Health Corp (PAHC)	2026-06-30	$61.42M	-9.7%
Supernus Pharmaceuticals, Inc. (SUPN)	2025-12-31	$128.45M	+85.3%

Compare GPCR, ACAD, LGND, AMPH side by side · Screen every company in Pharmaceutical Preparations ↗